Objective To investigate the effect of sodium ozagrel combined with edaravone on serum Creactive protein (CRP) and prognosis in patients with acute cerebral infarction. Methods 98 patients with acute cerebral infarction in neurology department of our hospital were divided into control group and observation group, according to the order of admission treatment, 49 cases in each group. On the basis of routine treatment such as dehydration, hypotension and symptomatic treatment, the control group was treated with edaravone, while the observation group was treated with ozagrel sodium combined with edaravone. Both groups were treated for 14 days. The serum CRP levels of the two groups were detected, and the NIHSS and CSS scores, the total effective rate of treatment and the occurrence of adverse reactions were compared. Results The serum CRP level of patients in the observation group was significantly decreased 14 days after treatment compared with that before treatment (P＜0.05), and the NIHSS and CSS scores of patients were lower than those of the control group (P＜0.05). The total effective rate of the observation group was significantly higher than that of the control group (P＜0.05), while the incidence of adverse reactions was lower than that of the control group (P＜0.05). Conclusion Ozagrel sodium combined with edaravone can effectively reduce serum CRP levels, improve neurological function, improve treatment effect, and have higher safety in patients with acute cerebral infarction.